Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MPC2 | O95563 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10084638 | 0.98 | L3MBTL1 (0.46) | L3MBTL1MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL10066438 | 0.84 | L3MBTL1 (0.49) | L3MBTL1MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL12291731 | 0.81 | MAPT (0.46) | L3MBTL1MAPTKDM4EALDH1A1MEN1 | |
| Bromide SCHEMBL7477106 | 0.79 | GSK3B (0.50) | MAPTKDM4EALDH1A1NFKB1TDP1 | |
| SCHEMBL286868 | 0.78 | KDM4E (0.69) | L3MBTL1MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL622903 | 0.78 | L3MBTL1 (0.50) | L3MBTL1MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL10229549 | 0.78 | L3MBTL1 (0.44) | L3MBTL1MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL12288371 | 0.77 | PPARG (0.60) | L3MBTL1MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL10085213 | 0.77 | L3MBTL1 (0.45) | L3MBTL1MAPTKDM4EALDH1A1MEN1 | |
| Bromide SCHEMBL30518647 | 0.77 | P4HTM (0.44) | KDM4EALDH1A1MEN1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603507-B1 | SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | METABOLIC SOLUTIONS DEV CO LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| EP-2931274-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Metabolic Solutions Development Company LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-8946435-B2 | Synthesis for thiazolidinedione compounds | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140378687-A1 | Synthesis for Thiazolidinedione Compounds | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC | 2014-12-25 | — | — | US | disclosed |
| US-8895748-B2 | Synthesis for thiazolidinedione compounds | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2014-11-25 | — | — | US | disclosed |
| WO-2014093114-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20130211092-A1 | SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2603507-A1 | SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | Metabolic Solutions Development Company LLC (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012177956-A1 | PPAR-SPARING COMPOUNDS FOR USE IN THE TREATMENT OF DIABETES AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMAPNY, LLC (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012021467-A1 | SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211092-A1 | SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | PPARD, PPARG, PPARA | L3MBTL1 3279/4885MAPT 3537/4885KDM4E 1400/4885 |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | PPARD, PPARG, PPARA | L3MBTL1 4250/4885MAPT 137/4885KDM4E 2439/4885 |
| US-20140378687-A1 | Synthesis for Thiazolidinedione Compounds | PPARD, PPARG, PPARA | L3MBTL1 3279/4885MAPT 3537/4885KDM4E 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.